ly 303511 has been researched along with Prostatic Neoplasms in 2 studies
LY 303511: inhibitor of phosphatidylinositol 3-kinase
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kristof, AS | 1 |
| Pacheco-Rodriguez, G | 1 |
| Schremmer, B | 1 |
| Moss, J | 1 |
| Poh, TW | 1 |
| Pervaiz, S | 1 |
2 other studies available for ly 303511 and Prostatic Neoplasms
| Article | Year |
|---|---|
LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Topics: Animals; Antineoplastic Agents; Casein Kinase II; Cell Cycle; Cell Proliferation; Cells, Cultured; C | 2005 |
LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
Topics: Apoptosis; Caspase Inhibitors; Catalase; Cell Growth Processes; Cell Line, Tumor; Chromones; Enzyme | 2005 |